NURO (NeuroMetrix) Change In Receivables : $0.33 Mil (TTM As of Dec. 2024)

View and export this data going back to 2004. Start your Free Trial

What is NeuroMetrix Change In Receivables?

NeuroMetrix's change in receivables for the quarter that ended in Dec. 2024 was $-0.04 Mil. It means NeuroMetrix's Accounts Receivable increased by $0.04 Mil from Sep. 2024 to Dec. 2024 .

NeuroMetrix's change in receivables for the fiscal year that ended in Dec. 2024 was $0.33 Mil. It means NeuroMetrix's Accounts Receivable declined by $0.33 Mil from Dec. 2023 to Dec. 2024 .

NeuroMetrix's Accounts Receivable for the quarter that ended in Dec. 2024 was $0.19 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. NeuroMetrix's Days Sales Outstanding for the three months ended in Dec. 2024 was 30.21.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. NeuroMetrix's liquidation value for the three months ended in Dec. 2024 was $12.90 Mil.

NeuroMetrix Change In Receivables Historical Data

The historical data trend for NeuroMetrix's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroMetrix Change In Receivables Chart

NeuroMetrix Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

0.15

0.02

-0.34

0.13

0.33

NeuroMetrix Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															0.10	0.05	0.19	0.13	-0.04

NeuroMetrix Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.33 Mil.

NeuroMetrix (NAS:NURO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

NeuroMetrix's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.193	/	0.583	*	91
=	30.21

2. In Ben Graham's calculation of liquidation value, NeuroMetrix's accounts receivable are only considered to be worth 75% of book value:

NeuroMetrix's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	13.095	-	1.012	+	0.75 * 0.193	+	0.5 * 1.348
=	12.90

NeuroMetrix Change In Receivables Related Terms

Thank you for viewing the detailed overview of NeuroMetrix's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroMetrix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroMetrix Inc (NAS:NURO) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

4B Gill Street, Woburn, MA, USA, 01801

Website

https://www.neurometrix.com

NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical device.

Executives

Bradley M Fluegel	director	120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Thomas T Higgins	officer: Chief Financial Officer
Topline Capital Management, Llc	other: See Explanation in Footnotes	544 EUCLID STREET, SANTA MONICA CA 90402
Topline Capital Partners, Lp	10 percent owner	544 EUCLID STREET, SANTA MONICA CA 90402
Mcbirney Collin	other: See Explanation in Footnotes	544 EUCLID STREET, SANTA MONICA CA 90402
Shai Gozani	director, officer: Chairman, President and CEO	C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Francis X Mcgillin	officer: Senior VP, Consumer	C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Avermaete David Van	director	C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Krishnamurthy Balachandran	officer: S. VP and GM, International	C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Nancy E Katz	director	CALYPTE BIOMEDICAL CORP, 1265 HARBOR BAY PKWY, ALAHEDA CA 94502
Neurometrix Inc	officer: Senior Vice President & GM
Walter Christensen	officer: Sr. VP, Global Sales	C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Timothy R Surgenor	director	100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035
Deerfield Management Company, L.p. (series C)	10 percent owner	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p.	10 percent owner	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017